Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611001191987
Ethics application status
Approved
Date submitted
14/11/2011
Date registered
17/11/2011
Date last updated
14/07/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
The Predicting Glaucoma Progression Project
Query!
Scientific title
A study to examine the utility of an Ibopamine challenge test, to differentiate glaucoma patients whose disease is progressively worsening from those whose disease is stable.
Query!
Secondary ID [1]
273390
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Glaucoma
279167
0
Query!
Condition category
Condition code
Eye
279362
279362
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intraocular pressure (IOP) is dependent on the balance between the production of aqueous fluid within the eye and the rate at which aqueous leaves the eye through the trabecular meshwork (TM) in the angle of the eye’s anterior chamber. The medication Ibopamine (Trazyl: Pharmainvest SpA, Milano, Italy) which is a dopamine receptor agonist, will temporarily increase aqueous production and dilate the pupil. A healthy eye with healthy TM cells will overcome this increase, pump aqueous out of the eye at an increased rated and the patient will demonstrate no IOP rise when Ibopamine drops are applied topically to the eye, however there is evidence that those with glaucoma will exhibit a rise in IOP. It may be that patients whose glaucoma is progressively worsening, will demonstrate a larger increase in IOP when Ibopamine drops are applied topically to their eye compared with stable patients.
To undertake an Ibopamine challenge, the patient has their IOP measured and recorded using goldmann applanation tonometry seated at the slit lamp; they then had two drops of Ibopamine 2% solution instilled into their eye; lastly their IOP is re-measured 45 minutes after receiving the Ibopamine eye drops and the IOP results pre and post the challenge are compared.
Query!
Intervention code [1]
283722
0
Diagnosis / Prognosis
Query!
Intervention code [2]
283736
0
Early detection / Screening
Query!
Comparator / control treatment
Cases will be patients who have glaucoma which has historically been found to be progressing. Controls will be those whose glaucoma has been found to be stable. Both groups will receive the Ibopamine challenge and their results will be compared.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
285952
0
Intraocular pressure will be measured with the patient seated at the slit lamp using a goldmann applanation tonometer prior to and following the Ibopamine challenge. The test will be scored as either positive or negative. A positive challenge will be one in which the intraocular pressure has risen by at least 3 mmHg following the challenge. The proportion of those with a positive challenge will be compared between the group whose glaucoma has progressively worsened and the group whose glaucoma is stable.
Query!
Assessment method [1]
285952
0
Query!
Timepoint [1]
285952
0
45 minutes following the Ibopamine challenge test.
Query!
Secondary outcome [1]
294842
0
Intraocular pressure will be measured with the patient seated at the slit lamp using a goldmann applanation tonometer prior to and following the Ibopamine challenge. The difference between pre and post challenge intraocular pressure will be compared between the group whose glaucoma has progressively worsened and the group whose glaucoma is stable.
Query!
Assessment method [1]
294842
0
Query!
Timepoint [1]
294842
0
45 minutes following the Ibopamine challenge test.
Query!
Eligibility
Key inclusion criteria
Primary open angle glaucoma (POAG) as defined by: characteristic and corresponding visual field and optic disc findings which are consistent with glaucoma and an intraocular pressure on treatment of at least 20% less than that prior to treatment. Progression is based on a worsening of visual field loss on three consecutive visual field tests performed over at least the preceding 24 months. Stability is based on a stable visual field on at least three consecutive visual field tests performed over the preceding 24 months.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
90
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria will include: those with forms of glaucoma other than POAG (e.g angle-closure glaucoma, secondary glaucoma etc.), those who have undergone previous intraocular surgery (except cataract surgery), those who were unable to perform a reliable visual field test and those who were unable to give informed consent.
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Both cases and controls would be selected from those attending the Flinders Medical Centre and the Repatriation General Hospital eye outpatients department.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/12/2011
Query!
Actual
2/07/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
29/07/2013
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
3232
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment postcode(s) [1]
9013
0
5042 - Bedford Park
Query!
Funding & Sponsors
Funding source category [1]
284205
0
Self funded/Unfunded
Query!
Name [1]
284205
0
John Landers
Query!
Address [1]
284205
0
The Flinders Medical Centre
BEDFORD PARK 5042
South Australia
Query!
Country [1]
284205
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
John Landers
Query!
Address
The Flinders Medical Centre
BEDFORD PARK 5042
South Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
269162
0
None
Query!
Name [1]
269162
0
Query!
Address [1]
269162
0
Query!
Country [1]
269162
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
286166
0
the Southern Adelaide Clinical Human Research Ethics Committee
Query!
Ethics committee address [1]
286166
0
Query!
Ethics committee country [1]
286166
0
Query!
Date submitted for ethics approval [1]
286166
0
18/11/2011
Query!
Approval date [1]
286166
0
22/12/2011
Query!
Ethics approval number [1]
286166
0
Query!
Summary
Brief summary
Glaucoma is a blinding eye disease which can be treated by lowering eye pressure, or intraocular pressure (IOP). However some patients continue to get worse despite having an acceptably lowered IOP. IOP is determined by the production of aqueous fluid within the eye and the rate at which aqueous leaves the eye through the trabecular meshwork (TM). The eye-drop medication Ibopamine which temporarily increases aqueous production, has no effect on normal patients; however those with glaucoma will exhibit a rise in IOP when Ibopamine is applied. Possibly, patients whose glaucoma is progressively worsening despite having a low IOP measured in the clinic will demonstrate a larger increase in IOP with Ibopamine drops. We would like to recruit two groups of patients: one with glaucoma which is progressively deteriorating despite lowered IOP and one with stable glaucoma. We would then like to compare the change in their IOP when Ibopamine drops are applied to their eyes. Our aim is to validate this as a new test to predict which glaucoma patients will progress.
Query!
Trial website
Query!
Trial related presentations / publications
Ullrich K, Craig JE, Landers J. Ibopamine challenge test can be used to differentiate glaucoma suspects from glaucoma patients. Clin Exp Ophthalmol. 2014; 42: 342-6 Landers J, Ullrich K, Craig JE. Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases. Clin Exp Ophthalmol. Published Online First: 3 July 2015. DOI 10.1111/ceo.12569
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33391
0
A/Prof John Landers
Query!
Address
33391
0
Department of Ophthalmology
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK 5042
South Australia
Query!
Country
33391
0
Australia
Query!
Phone
33391
0
(+618) 8204 4219
Query!
Fax
33391
0
Query!
Email
33391
0
[email protected]
Query!
Contact person for public queries
Name
16638
0
John Landers
Query!
Address
16638
0
The Flinders Medical Centre
BEDFORD PARK 5042
South Australia
Query!
Country
16638
0
Australia
Query!
Phone
16638
0
(+618) 8204 4219
Query!
Fax
16638
0
Query!
Email
16638
0
[email protected]
Query!
Contact person for scientific queries
Name
7566
0
John Landers
Query!
Address
7566
0
The Flinders Medical Centre
BEDFORD PARK 5042
South Australia
Query!
Country
7566
0
Australia
Query!
Phone
7566
0
(+618) 8204 4219
Query!
Fax
7566
0
Query!
Email
7566
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases.
2015
https://dx.doi.org/10.1111/ceo.12569
Embase
Ibopamine challenge testing becomes negative following successful trabeculectomy surgery.
2016
https://dx.doi.org/10.1111/ceo.12684
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF